A Seeking Alpha analyst initiated Buy on Novo Nordisk with $68 target, calling the bottom. Alpha Score 58 reflects mixed signals; competition from Eli Lilly remains a risk.
A Seeking Alpha contributor initiated coverage on Novo Nordisk with a Buy rating and a $68 price target. The analyst called the stock a non-consensus buy, arguing it has bottomed after a sharp decline from its 2023 highs.
The bearish case on Novo Nordisk is well known. Eli Lilly's Zepbound and Mounjaro have taken market share in the GLP-1 drug class. Pricing pressure has also weighed on the stock. The analyst's call runs directly against that sentiment.
The $68 target implies substantial upside from current levels. The analyst did not specify a timeline. The stock carries an Alpha Score of 58 out of 100, a Moderate label. That score suggests the stock is not in distressed territory. It also falls short of a strong buy signal.
A rebound in sales growth and positive clinical trial results for new indications like heart failure would support the call. Disappointing earnings or aggressive pricing moves from competitors would weaken it.
The analyst disclosed no position in the stock and no plans to initiate one in the next 72 hours. The call will be tested by upcoming earnings and trial readouts.
For more on Novo Nordisk, see the NVO stock page.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.